Bolt Biotherapeutics, Inc. (BOLT)
Largest Insider Buys in Sector
BOLT Stock Price History Chart
BOLT Stock Performance
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist …
Insider Activity of Bolt Biotherapeutics, Inc.
Over the last 12 months, insiders at Bolt Biotherapeutics, Inc. have bought $0 and sold $0 worth of Bolt Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Bolt Biotherapeutics, Inc. have bought $18.6M and sold $622,818 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,500 shares for transaction amount of $7,125 was made by Quinn William P. (Chief Financial Officer) on 2023‑12‑12.
List of Insider Buy and Sell Transactions, Bolt Biotherapeutics, Inc.
| 2023-12-12 | Chief Financial Officer | 7,500 0.0291% | $0.95 | $7,125 | -23.88% | |||
| 2023-12-06 | Chief Financial Officer | 2,500 0.008% | $0.78 | $1,955 | -17.59% | |||
| 2023-11-30 | Sale | director | 123,079 0.4308% | $0.86 | $105,614 | -10.81% | ||
| 2023-11-29 | Sale | director | 25,805 0.0954% | $0.91 | $23,379 | -14.79% | ||
| 2023-11-21 | Sale | director | 1,943 0.0071% | $0.90 | $1,751 | -10.77% | ||
| 2023-11-21 | Sale | 10 percent owner | 3,400 0.0125% | $0.90 | $3,060 | -10.77% | ||
| 2023-11-20 | Sale | director | 31,257 0.1173% | $0.92 | $28,756 | -15.33% | ||
| 2023-11-20 | Sale | 10 percent owner | 54,700 0.2053% | $0.92 | $50,324 | -15.33% | ||
| 2023-11-17 | Sale | director | 9,345 0.0354% | $0.93 | $8,691 | -16.40% | ||
| 2023-11-17 | Sale | 10 percent owner | 16,354 0.062% | $0.93 | $15,209 | -16.40% | ||
| 2023-11-16 | Sale | director | 8,571 0.0336% | $0.96 | $8,228 | -16.84% | ||
| 2023-11-16 | Sale | 10 percent owner | 15,000 0.0587% | $0.96 | $14,400 | -16.84% | ||
| 2023-06-06 | Chief Financial Officer | 1,829 0.0088% | $1.18 | $2,161 | -31.48% | |||
| 2022-07-13 | Sale | 800,000 6.5259% | $2.00 | $1.6M | -40.32% | |||
| 2021-12-08 | Chief Financial Officer | 5,000 0.0962% | $4.71 | $23,575 | -56.78% | |||
| 2021-12-06 | Chief Financial Officer | 35 0.0007% | $4.64 | $162 | -55.82% | |||
| 2021-12-06 | Chief Medical Officer | 411 0.0078% | $4.64 | $1,907 | -55.82% | |||
| 2021-06-04 | Chief Financial Officer | 1,221 0.0829% | $16.65 | $20,330 | -50.69% | |||
| 2021-06-04 | Chief Medical Officer | 917 0.0623% | $16.65 | $15,268 | -50.69% | |||
| 2021-02-09 | Sale | director | 62 0.0051% | $20.00 | $1,240 | -58.82% |
Insider Historical Profitability
| Novo Holdings A/S | 3703991 9.6778% | $0.50 | 1 | 1 | <0.0001% | |
| HEALY JAMES | director | 2754437 7.1968% | $0.50 | 1 | 0 | <0.0001% |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 2754437 7.1968% | $0.50 | 1 | 0 | <0.0001% |
| ENGLEMAN EDGAR | director | 251522 0.6572% | $0.50 | 1 | 7 | <0.0001% |
| Vivo Capital VIII, LLC | 10 percent owner | 111662 0.2918% | $0.50 | 1 | 5 | <0.0001% |